Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Trial Profile

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms START-CKD
  • Sponsors Amgen
  • Most Recent Events

    • 07 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Oct 2017, reported by ClinicalTrials.gov record.
    • 15 Feb 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
    • 15 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top